Perspective beyond cancer genomics: bioenergetics of cancer stem cells.

Yonsei Medical Journal
Hideshi IshiiMasaki Mori

Abstract

Although the notion that cancer is a disease caused by genetic and epigenetic alterations is now widely accepted, perhaps more emphasis has been given to the fact that cancer is a genetic disease. It should be noted that in the post-genome sequencing project period of the 21st century, the underlined phenomenon nevertheless could not be discarded towards the complete control of cancer disaster as the whole strategy, and in depth investigation of the factors associated with tumorigenesis is required for achieving it. Otto Warburg has won a Nobel Prize in 1931 for the discovery of tumor bioenergetics, which is now commonly used as the basis of positron emission tomography (PET), a highly sensitive noninvasive technique used in cancer diagnosis. Furthermore, the importance of the cancer stem cell (CSC) hypothesis in therapy-related resistance and metastasis has been recognized during the past 2 decades. Accumulating evidence suggests that tumor bioenergetics plays a critical role in CSC regulation; this finding has opened up a new era of cancer medicine, which goes beyond cancer genomics.

References

Sep 1, 1994·Molecular and Cellular Biology·B B KoenigR A Grant
Nov 2, 2001·Nature·T ReyaI L Weissman
Dec 4, 2001·Genes & Development·P W Ingham, A P McMahon
Sep 5, 2002·Nature Reviews. Cancer·Sanjiv Sam Gambhir
Mar 12, 2003·Proceedings of the National Academy of Sciences of the United States of America·Muhammad Al-HajjMichael F Clarke
Apr 21, 2005·Proceedings of the National Academy of Sciences of the United States of America·Arvind RamanathanStuart L Schreiber
May 27, 2006·Science·Satoaki MatobaPaul M Hwang
May 27, 2006·Science·Ken Garber
Aug 18, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Niven MehraEmile E Voest
Aug 22, 2006·Nature Reviews. Molecular Cell Biology·Sarah J Bray
Nov 1, 2006·Laboratory Investigation; a Journal of Technical Methods and Pathology·Brenton Thomas TanIrving L Weissman
Nov 24, 2006·Nature·Lucia Ricci-VitianiRuggero De Maria
Jan 11, 2007·Proceedings of the National Academy of Sciences of the United States of America·M E PrinceL E Ailles
May 9, 2007·Frontiers in Bioscience : a Journal and Virtual Library·Antonio GiordanoIgnazio R Marino
Jun 6, 2007·Cancer Cell International·Jayesh SagarAlexander Seifalian
Jun 21, 2007·Molecular Cancer Research : MCR·Sebastian KuhnMargot Zöller
Jul 13, 2007·Stem Cell Reviews·Tzung-Hai Yen, Nicholas A Wright
Sep 28, 2007·Biochemical and Biophysical Research Communications·Kentaro HosokawaToshio Suda
Jan 8, 2008·Cell Metabolism·Ralph J DeBerardinisCraig B Thompson
Apr 16, 2008·Experimental Cell Research·Hiroshi Kondoh
Aug 19, 2009·Antioxidants & Redox Signaling·Giovambattista PaniPaola Chiarugi
Sep 3, 2009·Journal of Cellular Physiology·Pernilla Eliasson, Jan-Ingvar Jönsson
Oct 29, 2009·Biochemical and Biophysical Research Communications·Hiromitsu HoshinoHideshi Ishii
Dec 19, 2009·Proceedings of the National Academy of Sciences of the United States of America·Norikatsu MiyoshiMasaki Mori

❮ Previous
Next ❯

Citations

Jun 12, 2012·ChemMedChem·Carlotta Granchi, Filippo Minutolo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Related Papers

Science China. Life Sciences
Hui YangKunLiang Guan
Science China. Life Sciences
GuoQing LiZhuChu Chen
Pharmacology & Therapeutics
Mohita UpadhyayPerumal Vivekanandan
Endocrine-related Cancer
L Hilakivi-ClarkeRichard G Pestell
Nihon rinsho. Japanese journal of clinical medicine
H Imura
© 2021 Meta ULC. All rights reserved